MCID: FLL003
MIFTS: 36

Fallopian Tube Endometrioid Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Endometrioid Adenocarcinoma:

Name: Fallopian Tube Endometrioid Adenocarcinoma 12 15 73
Endometrioid Carcinoma of the Fallopian Tube 12
Fallopian Tube Endometrioid Neoplasm 12
Fallopian Tube Endometrioid Cancer 12
Fallopian Tube Endometrioid Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5831
NCIt 50 C40111 C6279

Summaries for Fallopian Tube Endometrioid Adenocarcinoma

Disease Ontology : 12 A fallopian tube adenocarcinoma that derives from endometrial epithelial cells of glandular origin.

MalaCards based summary : Fallopian Tube Endometrioid Adenocarcinoma, also known as endometrioid carcinoma of the fallopian tube, is related to cervical adenocarcinoma and breast papillomatosis. An important gene associated with Fallopian Tube Endometrioid Adenocarcinoma is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are Bladder cancer and Platinum drug resistance. The drugs Paclitaxel and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and ovary, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and homeostasis/metabolism

Related Diseases for Fallopian Tube Endometrioid Adenocarcinoma

Diseases related to Fallopian Tube Endometrioid Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 cervical adenocarcinoma 10.1 CDKN2A ERBB2
2 breast papillomatosis 10.1 CDKN2A ERBB2
3 meningeal melanocytoma 10.1 CDKN2A MME
4 vulval paget's disease 10.1 CDKN2A ERBB2
5 breast benign neoplasm 10.1 ERBB2 MME
6 vulva adenocarcinoma 10.1 CDKN2A ERBB2
7 thoracic benign neoplasm 10.1 ERBB2 MME
8 cervix endometriosis 10.1 CALB2 MME
9 malignant leydig cell tumor 10.1 CALB2 MME
10 adenofibroma 10.1 CALB2 MME
11 rete testis adenocarcinoma 10.1 CALB2 MME
12 mixed cell type cancer 10.1 ERBB2 MME
13 lymphohistiocytoid mesothelioma 10.1 CALB2 CDKN2A
14 ewing's family of tumors 10.1 CDKN2A ERBB2
15 spermatocele 10.1 CALB2 MME
16 acute lymphoblastic leukemia, childhood 10.1 CDKN2A MME
17 rete testis neoplasm 10.1 CALB2 MME
18 cystadenofibroma 10.1 CALB2 MME
19 tonsil cancer 10.1 CDKN2A ERBB2
20 liposarcoma 10.1 CALB2 CDKN2A
21 mucinous bronchioloalveolar adenocarcinoma 10.1 CALB2 CDKN2A
22 breast fibroadenoma 10.1 ERBB2 MME
23 barrett's adenocarcinoma 10.1 CDKN2A ERBB2
24 pancreatic mucinous cystadenoma 10.1 CALB2 MME
25 lung combined type small cell carcinoma 10.1 MME MYOG
26 in situ carcinoma 10.1 CDKN2A ERBB2
27 pleural cancer 10.1 CALB2 CDKN2A
28 esophageal disease 10.1 CDKN2A ERBB2
29 ovarian brenner tumor 10.1 CALB2 MME
30 leukemia, acute lymphoblastic 3 10.1 CDKN2A MME
31 carcinosarcoma 10.1 ERBB2 MME
32 conventional leiomyosarcoma 10.1 CDKN2A MYOG
33 bladder disease 10.1 CDKN2A ERBB2
34 nephrogenic adenofibroma 10.0 MME MYOG
35 respiratory system cancer 10.0 CDKN2A ERBB2
36 malignant pleural mesothelioma 10.0 CALB2 CDKN2A
37 acute lymphocytic leukemia 10.0 CDKN2A MME
38 endometrial adenocarcinoma 10.0 CDKN2A ERBB2
39 uterine carcinosarcoma 10.0 ERBB2 MME
40 spindle cell liposarcoma 10.0 CALB2 MYOG
41 early invasive cervical adenocarcinoma 10.0 CDKN2A INSM1
42 cervix uteri carcinoma in situ 10.0 CDKN2A INSM1
43 uterus carcinoma in situ 10.0 CDKN2A INSM1
44 renal cell carcinoma, papillary, 1 10.0 ERBB2 MME
45 microinvasive cervical squamous cell carcinoma 10.0 INSM1 PTPRN
46 reproductive system disease 9.9 CDKN2A ERBB2 PTPRN
47 lung cancer susceptibility 3 9.9 CALB2 CDKN2A ERBB2
48 gastrointestinal system cancer 9.9 CDKN2A ERBB2
49 wilms tumor 1 9.8 CALB2 ERBB2 MYOG
50 pre-malignant neoplasm 9.8 CDKN2A ERBB2 INSM1

Graphical network of the top 20 diseases related to Fallopian Tube Endometrioid Adenocarcinoma:



Diseases related to Fallopian Tube Endometrioid Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Endometrioid Adenocarcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 8.92 CALB2 CDKN2A ERBB2 MYOG

MGI Mouse Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 CDKN2A ERBB2 INSM1 MME MYOG PTPRN
2 respiratory system MP:0005388 8.92 CDKN2A ERBB2 INSM1 MYOG

Drugs & Therapeutics for Fallopian Tube Endometrioid Adenocarcinoma

Drugs for Fallopian Tube Endometrioid Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
3
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 38904 498142
4
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
6
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
7
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
8
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
9
Gemcitabine Approved Phase 3 95058-81-4 60750
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
12
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
13
Maleic acid Experimental Phase 2, Phase 3 110-16-7 444266
14 Immunoglobulin G Phase 3,Phase 2,Phase 1
15 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
17 Antibodies Phase 3,Phase 2,Phase 1
18 Immunoglobulins Phase 3,Phase 2,Phase 1
19 Immunologic Factors Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
21 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
24 Mitogens Phase 3,Phase 2,Phase 1
25 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
29 Carotenoids Phase 3
30 Micronutrients Phase 3
31 Trace Elements Phase 3
32 Protein Kinase Inhibitors Phase 2, Phase 3
33 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
34 topoisomerase I inhibitors Phase 2, Phase 3
35 taxane Phase 3
36 Antimetabolites, Antineoplastic Phase 3
37 Antiviral Agents Phase 3
38 Antimetabolites Phase 3
39 Anti-Infective Agents Phase 3
40 Immunosuppressive Agents Phase 3,Phase 2
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
43
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
44 Immunoconjugates Phase 2
45 Maytansine Phase 2
46 Antineoplastic Agents, Alkylating Phase 2
47 Alkylating Agents Phase 2
48 Antirheumatic Agents Phase 2
49
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
50
Cisplatin Approved Phase 1 15663-27-1 2767 441203 84093

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
3 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
4 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
5 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
6 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
7 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
8 Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Participants With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT03587311 Phase 2 Paclitaxel
9 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
10 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02923739 Phase 2 Paclitaxel
11 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02853318 Phase 2 Cyclophosphamide
12 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
13 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
14 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Active, not recruiting NCT01097746 Phase 2 Carboplatin;Paclitaxel
15 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
16 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
17 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors Recruiting NCT03641287 Not Applicable
18 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Fallopian Tube Endometrioid Adenocarcinoma

Genetic Tests for Fallopian Tube Endometrioid Adenocarcinoma

Anatomical Context for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Endometrioid Adenocarcinoma:

41
Lung, Breast, Ovary, Pancreas, Cervix, Testis, Uterus

Publications for Fallopian Tube Endometrioid Adenocarcinoma

Articles related to Fallopian Tube Endometrioid Adenocarcinoma:

# Title Authors Year
1
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a case of report and review of the literature. ( 19457622 )
2010
2
Mixed serous and endometrioid carcinoma of the fallopian tube: a case report with literature review. ( 15991543 )
2005
3
Endometrioid carcinoma of the fallopian tube resembling a female adnexal tumor of probable wolffian origin. ( 15322493 )
2004
4
A case of endometrioid carcinoma of the fallopian tube mimicking an adnexal tumor of probable Wolffian origin. ( 10379682 )
1999
5
Primary endometrioid carcinoma of the fallopian tube. ( 8677782 )
1996
6
Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. ( 8946874 )
1996
7
Microcystic endometrioid carcinoma of the fallopian tube simulating an adnexal tumour of probable wolffian origin. ( 8314244 )
1993
8
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a report of six cases. ( 1582746 )
1992
9
Endometrioid carcinoma of the fallopian tube: pathology and clinical outcome. ( 1972104 )
1990
10
Endometrioid carcinoma of the fallopian tube. ( 683640 )
1978

Variations for Fallopian Tube Endometrioid Adenocarcinoma

Expression for Fallopian Tube Endometrioid Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Endometrioid Adenocarcinoma.

Pathways for Fallopian Tube Endometrioid Adenocarcinoma

Pathways related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.82 CDKN2A ERBB2
2 10.49 CDKN2A ERBB2

GO Terms for Fallopian Tube Endometrioid Adenocarcinoma

Biological processes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.5 CDKN2A INSM1 MYOG
2 cellular response to growth factor stimulus GO:0071363 9.26 ERBB2 MYOG
3 positive regulation of cell cycle arrest GO:0071158 9.16 INSM1 MYOG
4 replicative senescence GO:0090399 8.96 CDKN2A MME
5 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 CDKN2A ERBB2

Molecular functions related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin DNA binding GO:0031490 8.62 INSM1 MYOG

Sources for Fallopian Tube Endometrioid Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....